Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Xetra  >  Evotec SE    EVT   DE0005664809

EVOTEC SE

(EVT)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsMarketScreener StrategiesAnalyst Recommendations

Evotec : to attend upcoming investor conferences

share with twitter share with LinkedIn share with facebook
share via e-mail
0
05/16/2019 | 10:13am EDT

Evotec SE (Frankfurt Stock Exchange: EVT, MDAX/TecDAX, ISIN: DE0005664809) announced today that its management will be presenting at and attending the following upcoming conferences.

Berenberg Conference USA 2019, Tarrytown, NY, USA

Date: Tuesday, 21 May 2019, Presentation: 21 May 2019, 04.45 pm EDT (09.45 pm BST, 10.45 pm CEST)

Venue: Tarrytown, NY, USA

Attendee: Dr Werner Lanthaler, Chief Executive Officer

2019 RBC Capital Markets Global Healthcare Conference, New York, NY, USA

Date: Wednesday, 22 May 2019, Presentation: 22 May 2019, 10.30 am EDT (03.30 pm BST, 04.30 pm CEST)

Venue: New York, NY, USA

Attendee: Dr Werner Lanthaler, Chief Executive Officer

dbAccess Berlin Conference 2019, Berlin, Germany

Date: Wednesday, 05 June 2019, Presentation: 05 June 2019, 05.15 pm CEST (04.15 pm BST, 11.15 am EDT)

Venue: Berlin, Germany

Attendee: Enno Spillner, Chief Financial Officer

Jefferies 2019 Healthcare Conference, New York, NY, USA

Date: Thursday, 06 June 2019, Presentation: 06 June 2019, 03.30 pm EDT (08.30 pm BST, 09.30 pm CEST)

Venue: New York, NY, USA

Attendee: Dr Werner Lanthaler, Chief Executive Officer

FORWARD LOOKING STATEMENTS

Information set forth in this press release contains forward-looking statements, which involve a number of risks and uncertainties. The forward-looking statements contained herein represent the judgement of Evotec as of the date of this press release. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any such statements to reflect any change in our expectations or any change in events, conditions or circumstances on which any such statement is based.

Contact:

Tel: +49. (0)40.560 81-255

Fax: +49. (0)40.560 81-333

Web: www.evotec.com

(C) 2019 Electronic News Publishing, source ENP Newswire

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on EVOTEC SE
08:45aEVOTEC : Sensyne health, the university of oxford, osi, and oui create new bridg..
AQ
06/24EVOTEC : Sensyne health, the university of oxford, osi, and oui create new bridg..
EQ
06/20EVOTEC : Resolutions of the Annual General Meeting 2019 of Evotec SE
AQ
06/19EVOTEC : Resolutions of the annual general meeting 2019 of evotec se
EQ
06/13EVOTEC : bags US$23.8m to fight tuberculosis
AQ
06/12EVOTEC : bags $23.8m to fight tuberculosis
AQ
06/11EVOTEC : receives $ 23.8 m grant to join the global fight against tuberculosis
AQ
06/10EVOTEC : Receives $ 23.8 m grant to join the global fight against tuberculosis
EQ
06/06EVOTEC : and Celgene further expand iPSC collaboration including new cell type
AQ
06/05EVOTEC : And celgene further expand ipsc collaboration including new cell type
EQ
More news
Financials (€)
Sales 2019 417 M
EBIT 2019 73,7 M
Net income 2019 53,5 M
Finance 2019 3,00 M
Yield 2019 -
P/E ratio 2019 67,08
P/E ratio 2020 65,60
EV / Sales 2019 8,82x
EV / Sales 2020 7,66x
Capitalization 3 686 M
Chart EVOTEC SE
Duration : Period :
Evotec SE Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends EVOTEC SE
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 7
Average target price 26,9 €
Spread / Average Target 9,1%
EPS Revisions
Managers
NameTitle
Werner Lanthaler Chief Executive Officer
Wolfgang Plischke Chairman-Supervisory Board
Craig L. Johnstone Chief Operating Officer & Member-Management Board
Enno Spillner Chief Financial Officer
Cord E. Dohrmann Chief Scientific Officer
Sector and Competitors
1st jan.Capitalization (M$)
EVOTEC SE41.66%3 664
IQVIA HOLDINGS INC35.52%26 223
LONZA GROUP28.39%24 012
CELLTRION, INC.--.--%20 953
INCYTE CORPORATION36.69%17 061
EXACT SCIENCES CORPORATION80.30%13 037